JP4716655B2 - 抗炎症剤としてのモノ−およびジアシルグリセロールのグリコシドの使用 - Google Patents

抗炎症剤としてのモノ−およびジアシルグリセロールのグリコシドの使用 Download PDF

Info

Publication number
JP4716655B2
JP4716655B2 JP2003545294A JP2003545294A JP4716655B2 JP 4716655 B2 JP4716655 B2 JP 4716655B2 JP 2003545294 A JP2003545294 A JP 2003545294A JP 2003545294 A JP2003545294 A JP 2003545294A JP 4716655 B2 JP4716655 B2 JP 4716655B2
Authority
JP
Japan
Prior art keywords
inflammatory
compound
octadeca
hydrogen
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2003545294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005513023A (ja
JP2005513023A5 (enExample
Inventor
エリック・ラーセン
アーサラン・カラスミ
セレン・ブレッガー・クリステンセン
ラース・ポースクヤー・クリステンセン
キルステン・ブラント
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aarhus Universitet
Rigshospitalet
Original Assignee
Aarhus Universitet
Rigshospitalet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aarhus Universitet, Rigshospitalet filed Critical Aarhus Universitet
Publication of JP2005513023A publication Critical patent/JP2005513023A/ja
Publication of JP2005513023A5 publication Critical patent/JP2005513023A5/ja
Application granted granted Critical
Publication of JP4716655B2 publication Critical patent/JP4716655B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
JP2003545294A 2001-11-21 2002-11-21 抗炎症剤としてのモノ−およびジアシルグリセロールのグリコシドの使用 Expired - Lifetime JP4716655B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US33208401P 2001-11-21 2001-11-21
US60/332,084 2001-11-21
US34160901P 2001-12-18 2001-12-18
US60/341,609 2001-12-18
US35839102P 2002-02-22 2002-02-22
US60/358,391 2002-02-22
PCT/DK2002/000783 WO2003043613A2 (en) 2001-11-21 2002-11-21 Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010142945A Division JP2010215660A (ja) 2001-11-21 2010-06-23 抗炎症剤としてのモノ−およびジアシルグリセロールのグリコシドの使用

Publications (3)

Publication Number Publication Date
JP2005513023A JP2005513023A (ja) 2005-05-12
JP2005513023A5 JP2005513023A5 (enExample) 2006-03-02
JP4716655B2 true JP4716655B2 (ja) 2011-07-06

Family

ID=27406836

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003545294A Expired - Lifetime JP4716655B2 (ja) 2001-11-21 2002-11-21 抗炎症剤としてのモノ−およびジアシルグリセロールのグリコシドの使用
JP2010142945A Pending JP2010215660A (ja) 2001-11-21 2010-06-23 抗炎症剤としてのモノ−およびジアシルグリセロールのグリコシドの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010142945A Pending JP2010215660A (ja) 2001-11-21 2010-06-23 抗炎症剤としてのモノ−およびジアシルグリセロールのグリコシドの使用

Country Status (9)

Country Link
US (2) US7084122B2 (enExample)
EP (1) EP1453844B1 (enExample)
JP (2) JP4716655B2 (enExample)
CN (1) CN100469784C (enExample)
AU (1) AU2002366210A1 (enExample)
DK (1) DK1453844T3 (enExample)
NO (1) NO334587B1 (enExample)
PL (2) PL213644B1 (enExample)
WO (1) WO2003043613A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004153D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004151D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004152D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
AR035700A1 (es) * 2001-05-08 2004-06-23 Astrazeneca Ab Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
SE0102640D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
SE0203304D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Coumpounds
JP3914519B2 (ja) * 2003-06-06 2007-05-16 株式会社スピルリナ研究所 グリセロ糖脂質化合物を含有してなるリパーゼ活性阻害剤
US7758902B2 (en) * 2003-09-12 2010-07-20 Access Business Group International Llc Cytokine modulators and related methods of use
WO2005025586A1 (en) * 2003-09-12 2005-03-24 Access Business Group International Llc Cytokine modulators and related method of use
US7758903B2 (en) 2003-09-12 2010-07-20 Access Business Group International Llc Cytokine modulators and related methods of use
US20070269540A1 (en) * 2006-05-16 2007-11-22 Morishita Jintan Co., Ltd. Fat metabolism improving agent
JP3790767B2 (ja) * 2004-06-30 2006-06-28 森下仁丹株式会社 脂肪代謝改善組成物
JP4866067B2 (ja) * 2005-11-22 2012-02-01 株式会社ファンケル メラニン産生抑制剤
US8435588B2 (en) 2005-11-23 2013-05-07 The Coca-Cola Company High-potency sweetener composition with an anti-inflammatory agent and compositions sweetened therewith
EP2041151B1 (en) * 2006-07-03 2011-09-14 Hyben Vital Licens ApS A method of preparing a glycoside of a mono- or diacylglycerol product from a plant material
US7547455B2 (en) * 2006-09-20 2009-06-16 Academia Sinica Cancer and inflammatory disorder treatment
KR100772078B1 (ko) 2006-11-07 2007-10-31 한국기초과학지원연구원 갈조류 지충이로부터 분리된 신규모노갈락토실디아실글리세롤 화합물
JPWO2008108001A1 (ja) * 2007-03-02 2010-06-10 株式会社東洋新薬 ガラクト脂質
MX2010006955A (es) * 2007-12-21 2010-12-14 Finzelberg Gmbh & Co Kg Preparaciones con extractos de escaramujo y metodo para producir extractos de escaramujo.
NZ567712A (en) * 2008-04-24 2010-11-26 Fonterra Cooperative Group Ltd Compositions and methods for maintaining bone health or reducing bone loss
EP2288361B1 (de) 2008-05-06 2013-08-21 Finzelberg GmbH & Co. KG Zistrosenextrakt mit angereicherten sekundären pflanzeninhaltsstoffen
EP2349281A1 (en) * 2008-10-30 2011-08-03 Hyben Vital Licens ApS Composition comprising a glycoside of a mono- or diacyiglycerol compound and an oil rich in n-3 polyunsaturated fatty acids, a method of producing the composition and use of the composition
DK177605B1 (en) 2010-03-16 2013-11-18 Hyben Vital Licens Aps Compositions of rose hips enriched with seeds of rose hips and their use as anti-inflammatory natural medicine for alleviating/reducing symptoms associated with inflammation and joint diseases such as arthritis and/or osteo-arthritis
EP2389816A1 (en) 2010-05-25 2011-11-30 Nestec S.A. Synergistic antioxidant composition
WO2011161655A1 (en) 2010-06-25 2011-12-29 Horphag Research (Ip) Pre Ltd Composition for improving sexual wellness
TWI558403B (zh) * 2013-06-04 2016-11-21 中央研究院 富含半乳糖脂之植物萃取物及其用途
JP6339426B2 (ja) * 2014-06-30 2018-06-06 株式会社ファンケル グリセロ糖脂質を含有する組成物の製造方法及びグリセロ糖脂質含有組成物
CA3029005A1 (en) * 2016-06-27 2018-01-04 Ohio State Innovation Foundation Liponucleotide-based therapy for ards
CN106983763B (zh) * 2017-04-25 2021-04-20 中国海洋大学 单半乳糖基二酰基甘油酯及其制备方法与用途
CN110201026B (zh) * 2019-07-15 2021-09-24 青岛农业大学 一种非抗生素型结肠炎修复制剂
KR102780726B1 (ko) * 2022-12-30 2025-03-13 주식회사 미래생명자원 테트라셀미스 츄이로부터 분리한 신규 화합물 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05271270A (ja) * 1992-03-27 1993-10-19 Nippon Paper Ind Co Ltd 糖ーグリセロール誘導体とその合成法
JP3298723B2 (ja) * 1993-03-30 2002-07-08 武田食品工業株式会社 発癌プロモーション抑制組成物
WO1994024984A2 (en) * 1993-04-30 1994-11-10 Winget Rodner R Anti-inflammatory compositions containing eicosapentaenoic acid bearing monogalactosyldiacylglycerol and methods relating thereto
JPH07149786A (ja) 1993-11-26 1995-06-13 Sagami Chem Res Center グリセロ糖脂質及び発癌プロモーター阻害剤
CA2142153A1 (en) * 1994-03-04 1995-09-05 Jacques Banville Sulfated .beta.-glycolipid derivatives as cell adhesion inhibitors
US5663151A (en) 1994-03-04 1997-09-02 Bristol-Myers Squibb Company Sulfated α-glycolipid derivatives as cell adhesion inhibitors
US5486536A (en) * 1994-08-15 1996-01-23 The Regents Of The University Of Michigan Sulfatides as anti-inflammatory compounds
DE19634021A1 (de) * 1996-08-23 1998-02-26 Beiersdorf Ag Antiadhäsive Glycoglycerolipide
DE19634019A1 (de) 1996-08-23 1998-02-26 Beiersdorf Ag Gegen Mikroogranismen, Viren, Parasiten und Protozoen wirksame Glycoglycerolipide
DE19700774A1 (de) * 1997-01-13 1998-07-16 Hoechst Ag Antiadhäsive Sulfatid-Mimetika
US6024960A (en) * 1998-04-17 2000-02-15 Otto Torbjorn Hansen And Marianne Hansen Rose-hip formulations as anti-inflammatory natural medicine for alleviating/reducing symptoms associated with inflammation and arthritis

Also Published As

Publication number Publication date
JP2005513023A (ja) 2005-05-12
DK1453844T3 (da) 2014-02-10
WO2003043613A2 (en) 2003-05-30
CN1606563A (zh) 2005-04-13
US20030139350A1 (en) 2003-07-24
EP1453844A2 (en) 2004-09-08
AU2002366210A1 (en) 2003-06-10
NO20042112L (no) 2004-07-09
NO334587B1 (no) 2014-04-14
JP2010215660A (ja) 2010-09-30
EP1453844B1 (en) 2013-11-20
US7084122B2 (en) 2006-08-01
CN100469784C (zh) 2009-03-18
AU2002366210A8 (en) 2003-06-10
WO2003043613A3 (en) 2004-03-25
US20050049205A1 (en) 2005-03-03
PL393941A1 (pl) 2011-06-20
PL213644B1 (pl) 2013-04-30
PL370888A1 (en) 2005-05-30

Similar Documents

Publication Publication Date Title
JP4716655B2 (ja) 抗炎症剤としてのモノ−およびジアシルグリセロールのグリコシドの使用
JP3065710B2 (ja) 抗炎症剤
EP2415749A1 (en) New salvianolic acid compound l, preparation method and use thereof
CN1191488A (zh) 金盏花属糖苷用于治疗牛皮癣
EP2981256B1 (en) Anti-inflammatory synergistic combinations comprising omega-3 fatty acid, tomato lycopene, lutein and carnosic acid
JPH08504403A (ja) ニームノキから誘導される治療用化合物
EP3542810B1 (en) Composition containing artemisia annua extract as effective ingredient for alleviating skin disease and preparation method therefor
US12186355B2 (en) Phytocomplex and selected extract of a meristematic cell line of a plant belonging to the genus melissa
JP4300120B2 (ja) 抗蠕虫性アントラキノン及びその使用方法
KR20230111626A (ko) 까나리 지질 추출물을 유효성분으로 포함하는 항염증용 조성물
US20130303602A1 (en) Novel pterocarpan compound or pharmaceutically acceptable salt thereof and pharmaceutical composition for prevention or treatment of metabolic disease or complication thereof, or for antioxidant containing the same as an active ingredient
KR20180054501A (ko) 개똥쑥 추출물을 유효성분으로 포함하는 피부질환을 개선시키기 위한 조성물 및 그 제조방법
Nnamani et al. Design and evaluation of nanostructured lipid carrier of Bergenin isolated from Pentaclethra macrophylla for anti-inflammatory effect on lipopolysaccharide-induced inflammatory responses in macrophages
JP4160532B2 (ja) 免疫を増強するための医薬組成物、およびポリア抽出物
US5260067A (en) Cytotropic heterogeneous molecular lipids (CHML) and process for preparing the same
EP1222925A2 (en) Kavalactone as TNF-alpha production inhibitor
KR101784294B1 (ko) 모과 추출물을 포함하는 뇌신경질환 예방 또는 치료용 의약 조성물
EP1734946B1 (en) Punicic acid for use to enhance immune response and treating inflammatory bowel disease
US11292807B2 (en) Molecules from seaweeds with anti-cancer activity
JP2010037245A (ja) 代謝活性化に好適な組成物
US20080268076A1 (en) Composition for Inhibiting Acyl-Coa:Cholesterol Acyltransferase
US12121504B1 (en) Method for producing 1,3-diolein from biomass
KR100569086B1 (ko) 간세포 보호활성을 갖는 고로쇠 잎 추출물 및 이로부터분리된 페놀성 화합물
KR102743581B1 (ko) 검은지느러미 빙어 추출물 또는 에메랄드 암치 추출물을 유효성분으로 포함하는 항염증용 조성물
KR100831757B1 (ko) 페리너스 속 버섯 또는 이노노투스 속 버섯의 균사체 배양물로부터 분리된 항산화 화합물 및 이를 포함하는 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090918

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091023

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091124

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091217

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100623

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20100813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100813

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100907

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110301

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110329

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4716655

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140408

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term